Brief: VolitionRx, Gyros Protein Awarded $1 Mln Grant To Collaborate On Lung Cancer Blood Test
05/12/2019 14:45
Dec 5 (Reuters) - VolitionRX Ltd VNRX.A :
* VOLITIONRX AND GYROS PROTEIN TECHNOLOGIES AWARDED AN
AGGREGATE
$1 MILLION+ EUROSTARS CASH GRANT TO COLLABORATE ON DEVELOPING A
LUNG CANCER BLOOD TEST
Source text for Eikon: ID:nPnbPJ3Kna
Further company coverage: VNRX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VolitionRX
See all newsBrief: Volitionrx -Files Preliminary Prospectus For 10,006,360 Shares Of Common Stock Offered By Selling Stockholder - SEC Filing
Brief: Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization
Brief: VolitionRX Limited Announces First Quarter 2026 Financial Results
Brief: Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
Brief: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test With Fujifilm Vet Systems